Lilly accused at trial of hiding Cymbalta ‘brain zap’ risk
The drugmaker faces as many as 5,000 cases claiming it downplayed Cymbalta’s withdrawal risks, which allegedly include electrical-shock sensations, vomiting and insomnia.
Eli Lilly and Co.
Articles
Lilly expands R&D outside Indy—again
State and city leaders spend millions each year to entice companies to move here and add jobs here. But for the second time in three months, Eli Lilly and Co. has shown that the biggest attraction to a company is talented workers.
Lilly, Anthem show high risk, high reward strategy can pay off
The CEOs of Eli Lilly and Anthem are being rewarded by investors for taking high-risk approaches to develop breakthrough drugs, make major acquisitions.
Indy’s top 11 acquisition deals, before Anthem-Cigna
Anthem’s $54 billion bid for rival insurer Cigna is twice the size of the next-largest acquisition in the Indianapolis area, which occurred nearly a decade ago.
Lilly posts lackluster profit but boosts full-year forecast
Eli Lilly and Co.’s profits plunged 18 percent in the second-quarter but still easily beat the lowered expectations of Wall Street analysts.
Alzheimer’s trials offer little certainty for investors, patients
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer’s drug.
Study shows Lilly’s Alzheimer’s drug has small but lasting benefit
New data released Wednesday morning suggest that Eli Lilly and Co.’s Alzheimer’s drug has a modest but lasting impact on the memory-sapping disease. But analysts worry the impact is too small to be meaningful.
Lilly faces moment of truth this week
The Indianapolis-based drugmaker on Wednesday will release new data from patients taking its Alzheimer’s drug that could show whether the drug has slowed the progression of their disease. That will show investors whether the 45 percent rise in Lilly’s stock price over the past year is justified.
Lilly partner Immunocore raises record $320 million
Immunocore Ltd., which this week achieved the biggest private fundraising by a European biotechnology firm in 10 years, plans to accelerate development of its cancer therapy using the money and seek expedited approval.
PROXY CORNER: Eli Lilly and Co.
Eli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
Clot risk in Lilly lung-cancer drug raises FDA concerns
The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, Food and Drug Administration staff said in a report Tuesday.
Indiana’s medical research ‘trade deficit’
Indiana's life sciences companies are spending four times more on medical research than the state's hospitals, doctors and univerities are receiving from such companies for research projects. That means Indiana is missing out on more than $80 million a year.
Resurgence of Eli Lilly is touching all corners of region
Central Indiana's economy is diverse, but Lilly is such a behemoth that its ups and downs reverberate statewide.
British court ruling backs patent protecting Lilly’s Alimta
Eli Lilly and Co. received some European legal backing for its top product, the lung cancer treatment Alimta, on Thursday when a British court upheld a patent protecting a vitamin regimen administered with the drug.
Lilly facing first trials over Cymbalta withdrawal symptoms
Eli Lilly and Co. has been ordered to face claims it misled consumers about “brain zaps” and other withdrawal side effects tied to its antidepressant Cymbalta in the first cases slated to be heard by juries.
Lilly drug regimen costing $9,200 a month scores zero in study
In a new scoring system for oncology drugs, a leading group of U.S. cancer doctors awarded a zero for overall benefit to a regimen featuring Alimta, Eli Lilly and Co.’s top-selling product.
Lilly buoyed by string of positive results from drug trials
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Startup aims to upend diabetes care with matchstick-size implant
Intarcia Therapeutics Inc. is betting its matchstick-size pump could take market share from Eli Lilly and Co., AstraZeneca Plc and Novo Nordisk A/S.
Eli Lilly says it has ‘no intention’ to spin off animal health unit
Eli Lilly stock rose 5.4 percent per share on Tuesday, its biggest daily increase since March 2009, after Elanco President Jeffrey Simmons was asked if Lilly might one day shed the unit in an initial public offering.
Fate of Eli Lilly’s potential $2B blockbuster insulin hangs on side effects
Lilly’s basal insulin peglispro proved more effective than the $7 billion blockbuster Lantus at controlling diabetics’ blood sugar, but it also had greater effect on patients’ livers and hearts. Analysts are unsure of its future.